Comparison of patient background between a real-world North American cohort and the Göteborg-2 trial.
Giuseppe ChiarelliMatthew DavisAlex StephensGiuseppe Ottone CirulliMarco FinatiNicholas J CorsiAkshay SoodShane TinsleyGiuseppe CarrieriAlberto BrigantiFrancesco MontorsiGiovanni LughezzaniNicolò BuffiCraig RogersFiras AbdollahPublished in: International journal of urology : official journal of the Japanese Urological Association (2024)
Our cohort had a lower biopsy rate and a lower incidence of non-csPCa diagnosis than both Göteborg cohorts, while still maintaining the same incidence of csPCa. This implies that the benefits of reducing non-csPCa diagnosis, as observed in the Experimental Göteborg cohort, are not necessarily replicable in U.S. "real-world practice" patients. Also noteworthy, we had a significantly higher percentage of Black men, who showed more aggressive disease.